De novo variants in *PLCG1* are associated with hearing impairment, ocular pathology, and cardiac defects

Mengqi Ma,1,2,* Yiming Zheng,1,2,12,* Shenzhao Lu,1,2 Xueyang Pan,1,2 Kim C. Worley,1 Lindsay C. Burrage,1 Lauren S. Blieden,1 Aimee Allworth,3 Wei-Liang Chen,3,13 Giuseppe Merla,4,5 Barbara Mandriani,6 Jill A. Rosenfeld,1 David Li-Kroeger,7 Debdeep Dutta,1,2 Shinya Yamamoto,1,2 Michael F. Wangler,1,2 Undiagnosed Diseases Network, Ian A. Glass,3,8,9 Sam Strohbehn,3 Elizabeth Blue,3,9,10 Paolo Prontera,11 Seema R. Lalani,1 Hugo J. Bellen,1,2,#

Affiliations:

1. Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA

2. Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, Houston, TX 77030, USA

3. Division of Medical Genetics, Department of Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA

4. Laboratory of Regulatory & Functional Genomics, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia 71013, Italy

5. Department of Molecular Medicine & Medical Biotechnology, University of Naples Federico II, Naples 80131, Italy

6. Department of Interdisciplinary Medicine, University of Bari "Aldo Moro", Bari 70121, Italy

7. Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA

8. Division of Genetic Medicine, Department of Pediatrics, University of Washington School of Medicine, Seattle, WA 98195, USA

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
9. Brotman Baty Institute, Seattle, WA 98195, USA

10. Institute for Public Health Genetics, University of Washington, Seattle, WA 98195, USA

11. Medical Genetics Unit, Hospital of Perugia, Perugia 06129, Italy

12. Current affiliation: State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Faculty of Medicine and Life Sciences, Xiamen University, Xiamen 361102, China

13. Current affiliation: Children's National Medical Center and George Washington University, Washington DC 20010, USA

* These authors contributed equally

# Correspondence: Hugo J. Bellen: hbellen@bcm.edu
Abstract

Phospholipase C isozymes (PLCs) hydrolyze phosphatidylinositol 4,5-bisphosphate into inositol 1,4,5-trisphosphate and diacylglycerol, important signaling molecules involved in many cellular processes. PLCG1 encodes the PLCγ1 isozyme that is broadly expressed. Hyperactive somatic mutations of PLCG1 are observed in multiple cancers, but only one germline variant has been reported. Here we describe three unrelated individuals with de novo heterozygous missense variants in PLCG1 (p.Asp1019Gly, p.His380Arg, and p.Asp1165Gly) who exhibit variable phenotypes including hearing loss, ocular pathology and cardiac septal defects. To model these variants in vivo, we generated the analogous variants in the Drosophila ortholog, small wing (sl). We created a null allele slT2A and assessed the expression pattern. sl is broadly expressed, including in wing discs, eye discs, and a subset of neurons and glia. Loss of sl causes wing size reductions, ectopic wing veins and supernumerary photoreceptors. We document that mutant flies exhibit a reduced lifespan and age-dependent locomotor defects. Expressing wild-type sl in slT2A mutant rescues the loss-of-function phenotypes whereas expressing the variants causes lethality. Ubiquitous overexpression of the variants also reduces viability, suggesting that the variants are toxic. Ectopic expression of an established hyperactive PLCG1 variant (p.Asp1165His) in the wing pouch causes severe wing phenotypes, resembling those observed with overexpression of the p.Asp1019Gly or p.Asp1165Gly variants, further arguing that these two are gain-of-function variants. However, the wing phenotypes associated with p.His380Arg overexpression are mild. Our data suggest that the PLCG1 de novo heterozygous missense variants are pathogenic and contribute to the features observed in the probands.

Keywords: Phospholipase C; Drosophila; phenotypic heterogeneity; PLCG1 gain-of-function variants
Introduction

The inositol lipid-specific phospholipase C (PLC) isozymes are key signaling proteins that play critical roles in transducing signals from hormones, growth factors, neurotransmitters, and many extracellular stimuli. The PLCs selectively hydrolyze phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). PIP2 functions as a membrane anchor for numerous proteins and affects membrane dynamics and ion transport. The two products, IP3 and DAG, are important intracellular second messengers involved in Ca\(^{2+}\) signaling regulation and protein kinase C signaling activation, respectively. Hence, PLC orchestrates diverse cellular processes and behaviors, including cell growth, differentiation, migration, and cell death. There are at least thirteen PLC isozymes grouped in 6 classes (β, δ, ε, γ, η, ζ) in mammals with similar enzymatic function, but each PLC has its own spectrum of activators, expression pattern, and subcellular distribution.

PLCG1 [MIM: 172420] encodes the PLCγ1 isozyme. PLCγ1 is directly activated by receptor tyrosine kinases (RTKs) as well as cytosolic receptors coupled to tyrosine kinases. Upon tyrosine phosphorylation, PLCγ1 undergoes conformational changes that release its autoinhibition upon which it associates with the plasma membrane to bind and hydrolyze its substrates. There is a second PLCγ isozyme, PLCγ2, encoded by PLCG2 [MIM: 600220]. Although these two isozymes have similar protein structure and activation mechanism, they are differentially expressed and regulated, and play non-redundant roles. PLCG2 is mostly expressed in cells of the hematopoietic system and mainly functions in immune response, causing human diseases associated with immune disorders. However, PLCG1 is ubiquitously expressed and is enriched in the central nervous system (CNS). Plcg1 is essential in mice, and a null allele causes embryonic lethality with developmental defects in the vascular, neuronal, and immune system. PLCG1 has emerged as a possible driver for cell proliferation, and increased expression level of PLCG1 has been observed in breast cancer, colon cancer, and squamous cell carcinoma. Moreover, hyperactive somatic mutations of PLCG1 have been observed in...
angiosarcomas and T cell leukemia/lymphomas\(^{35-37}\). However, the genotype-phenotype association of germline \(PLCG1\) variants has yet to be explored.

**Results**

**Individuals with \textit{de novo} heterozygous missense variants in \(PLCG1\) exhibit hearing impairment, ocular pathology, and cardiac defects**

Here, we report three unrelated individuals with \textit{de novo} heterozygous missense variants in \(PLCG1\) (GenBank: NM_002660.3). Proband 1 (c.3056A>G, p.Asp1019Gly) and proband 2 (c.1139A>G, p.His380Arg) were identified through the Undiagnosed Diseases Network (UDN)\(^{45}\) and proband 3 (c.3494A>G, p.Asp1165Gly) was identified via GeneMatcher\(^{46}\). The probands range in age from 5 years to 20 years. The phenotypes of the probands partially overlap but show a diverse spectrum. Pertinent shared features include deafness (probands 1 and 3), ophthalmologic abnormalities (probands 1 and 2), and cardiac septal defects (probands 1 and 3). Two of the three individuals show abnormal brain MRI (probands 1 and 2), and one has immune defects (proband 3). Additional variants identified in the probands are discussed in supplemental data. [\textit{As per medRxiv policy, the whole and detailed case history for the probands have been removed. To obtain more detailed information, please contact the authors}]\(^{47}\)

**The proband-associated missense \(PLCG1\) variants are located in conserved protein domains and are predicted to be deleterious**

\(PLCG1\) is predicted to be tolerant to loss-of-function alleles with a pLI score\(^{47}\) of 0.16, suggesting that loss of one copy of the gene is unlikely to cause haploinsufficiency in humans and consistent with the presence of many protein truncating variants in gnomAD\(^{48}\). However, the missense constraint Z score\(^{47}\)
of \textit{PLCG1} is 3.69, suggesting it is intolerant to missense variants. In addition, the prediction based on the DOMINO algorithm indicates that \textit{PLCG1} variants are likely to be dominant. The \textit{in-silico} pathogenicity predictions suggest that these variants are likely to be pathogenic (Table S1) based on MARRVEL.

The three variants identified from the probands map to different conserved domains of PLC\(\gamma\)1, and each variant affects an amino acid residue that is conserved from flies to humans (Figure 1A and Figure 1B). The p.Asp1019Gly and p.His380Arg variants map to the catalytic core domains, and the p.Asp1165Gly is in the C-terminal C2 domain. PLC\(\gamma\)1 contains other conserved domains including an N-terminal pleckstrin homology (PH) domain, four EF hand motifs, as well as a PLC\(\gamma\)-specific regulatory array that is composed of a split PH domain (sPH), two Src homology 2 (nSH2 and cSH2) domains and a Src homology 3 (SH3) domain.

\textit{small wing} (\textit{sl}) is the fly ortholog of human \textit{PLCG1}

To obtain information about the nature of the proband-associated variants, we utilize \textit{Drosophila} to model the variants \textit{in vivo}. Flies have three genes encoding PLC isozymes (Table S2). Among them, \textit{small wing} (\textit{sl}) is predicted to be the ortholog of \textit{PLCG1} with a DIOPT (DRSC Integrative Ortholog Prediction Tool) score of 17/18 (DIOPT version 9.0). The encoded proteins share 39\% identity and 57\% similarity and are composed of similar conserved domains (Figure 1A). \textit{sl} is also predicted to be the ortholog of \textit{PLCG2} with a DIOPT score of 12/18. These data suggest that \textit{sl} corresponds to two human genes encoding the PLC\(\gamma\) isozymes. We generated transgenic flies carrying the \textit{UAS-human PLCG1} cDNAs for both the reference (\textit{UAS-PLCG1\textit{Reference}}) and the variants (\textit{UAS-PLCG1}^{D1019G}, \textit{UAS-PLCG1}^{H380R}, and \textit{UAS-PLCG1}^{D1165G}). Given the high level of protein sequence homology and the conservation of the affected amino acids (Figure 1B), we also generated transgenic flies for the reference and analogous variants in the fly \textit{sl} cDNA, namely \textit{UAS-sl}\textit{WT} and \textit{UAS-sl}variants (\textit{UAS-sl}^{D1041G}, \textit{UAS-sl}^{H384R}, and \textit{UAS-sl}^{D1184G}).
sl is on the X chromosome, and several alleles of sl have been isolated or generated previously, including slF, slKO and slT2A (Figure 1C). slF carries a 13bp deletion in the third exon that leads to a frameshift and early stop gain. slF is a strong loss-of-function allele that causes small wing size, ectopic wing veins and extra R7 photoreceptors. slKO was generated by CRISPR-mediated genomic editing that removes nearly the entire gene. slT2A allele was generated by inserting an FRT-T2A-GAL4-polyA-FRT cassette as an artificial exon into the first coding intron of sl (Figure 1C). The polyA arrests transcription, and slT2A is a strong loss-of-function allele (Figure S1A). The T2A viral sequence triggers ribosomal skipping and leads to the production of GAL4 proteins that are expressed in the proper spatial and temporal pattern of sl. This allows us to assess the expression pattern of sl by driving the expression of a UAS-fluorescent protein, or to assess the function of variants by expressing the human UAS-reference/variant cDNAs. In addition, the cassette is flanked by two FRT sites so that it can be excised from the cells that express the gene in the presence of UAS-Flippase and revert the mutant phenotypes (Figure 1C).

We first assessed the expression pattern of sl by driving UAS-mCherry.nls (an mCherry that localizes to nuclei) with slT2A. sl is expressed in the 3rd larval wing discs and eye discs (Figure 2A), consistent with the loss-of-function phenotypes observed in the wings and eyes. The expression pattern of sl in the wing discs is not homogenous. Higher expression levels are observed in the anterior compartment and along both the anterior/posterior and dorsal/ventral compartment boundaries (Figure 2A). The hemizygous slT2A/Y male flies and the trans-heterozygous slT2A/slF or slT2A/slKO female flies show reduced wing size and ectopic wing veins (Figure 2B and Figure S1B), as well as additional photoreceptors in the eye (Figure 2C and Figure S1C). These phenotypes can be rescued by UAS-Flippase or by introducing a genomic rescue construct (Dp(1;3)DC313, Figure 1C) that covers the sl locus (Figure 2B and Figure 2C). These data show that all the observed phenotypes in slT2A mutants can be attributed to the loss of sl.

sl is expressed in the fly CNS and loss of sl causes longevity and locomotion defects.
Given that human *PLCG1* is highly expressed in the central nervous system (CNS) and that the probands present with neurologic phenotypes including hearing or vision deficits (Table 1), we investigated the expression pattern and the cell type specificity of *sl* in the CNS of flies. *sl* is expressed in the larval CNS as well as the adult brain, and co-staining with the pan-neuronal marker Elav and glial marker Repo show that *sl* is expressed in a subset of neurons and glia cells in the CNS (Figure 3A). We therefore assessed the longevity and climbing of *sl* flies. Compared to the wild-type *w* flies, *sl* hemizygous mutant flies show a shortened lifespan and a progressively reduced climbing ability. These phenotypes can be rescued by expression of the wild-type *sl* cDNA (*sl*/*Y; *UAS-slWT*) (Figure 3B).

**Functional assays in flies indicate that the *PLCG1* variants are toxic**

To assess the impact of the variants, we expressed the *sl* variant cDNAs in the *sl*/*Y* hemizygous mutant males (*sl*/*Y; *UAS-slvariant*) and compared their rescue ability with the wild-type *sl* (*sl*/*Y; *UAS-slWT*). As shown in Figure 4A, the *sl*/*Y* mutant flies (or the ones expressing a *UAS-Empty* control construct) have a slightly reduced eclosion rate but expression of the *slWT* cDNA fully rescues the percentage of eclosing progeny as measured by the Mendelian ratio. In contrast, expressing *slH384R* causes a severe reduction of the number of eclosing flies with very few escapers (*sl*/*Y; *UAS-slH384R*). Moreover, expression of the *slD1041G* or *slD1184G* leads to 100% lethality (Figure 4A). These data clearly indicate that the three variants are toxic.

Given that the expression of these *sl* cDNAs is performed in a null mutant background, we opted to assess the phenotypes associated with ectopic expression assays by overexpressing the wild-type or variant *sl* cDNAs using a strong ubiquitous driver, *Tub-GAL4*. Overexpression of *slWT* shows no impact on viability. However, overexpression of *slH384R* leads to ~36% lethality, while overexpression of *slD1041G* or *slD1184G* results in 100% lethality at the L1-L2 larval stage (Figure 4B). Hence, ubiquitous overexpression assays cause similar but less severe lethal phenotypes than the expression assays driven by *slT2A*. This difference
may arise from the different expression patterns and levels of Tub-GAL4 and slT2A. Importantly, slT2A drives expression in the cells that normally express sl. In summary, the data argue that the sl variants are likely to be gain-of-function or neomorphic alleles and that slD1041G and slD1184G are very strong toxic alleles whereas slH384R is a milder allele.

To compare the sl and PLCG1 associated phenotypes, we conducted similar assays using human PLCG1 cDNAs. Expression of PLCG1Reference in the slT2A/Y mutant flies (slT2A/Y; UAS-PLCG1Reference) (Figure 4A) reduces viability by 90%, while the ubiquitous expression of PLCG1Reference under the control of Tub-GAL4 (Tub-GAL4 > UAS-PLCG1Reference) reduces viability by 63% (Figure 4B). These data argue that the reference human PLCG1 cDNA is toxic in flies. Expression of PLCG1H380R in the slT2A/Y mutant flies (slT2A/Y; UAS-PLCG1H380R) leads to a modest increase in lethality when compared to PLCG1Reference (Figure 4A), whereas Tub-GAL4 > UAS-PLCG1H380R is not worse than PLCG1Reference (Figure 4B). In contrast, expression of PLCG1D1019G or PLCG1D1165G results in 100% lethality using either of the drivers (Figure 4A and 4B). In summary, expressing the human PLCG1 in flies induces toxicity, and PLCG1H380R has only slightly increased toxicity when compared to PLCG1Reference. However, the PLCG1D1019G or PLCG1D1165G variants display a severe gain of toxicity.

Since overexpressing fly slWT does not cause viability issues (Figure 4B), the observed toxicity associated with PLCG1Reference in flies may be due to the elevated expression of the human proteins. This hypothesis can be assessed by ectopic expression assays performed by raising the flies at different temperatures. The GAL4-UAS system is highly temperature-dependent since the promoter in the UAS construct contains an Hsp-70 promoter: at 29°C the expression level is much higher than at 25°C, and at 22°C the expression level is significantly lower than at 25°C. As shown in Figure 4C, the Tub-GAL4 > UAS-PLCG1Reference flies exhibit a high lethality ratio when raised at 29°C (~63% lethal). This lethality ratio decreased to ~43% when the flies are raised at 25°C whereas the flies are viable at 22°C. This shows that the toxicity is highly dependent on protein levels. Indeed, the expression levels can be further lowered by using a weak ubiquitous GAL4 driver, da-GAL4. The da-GAL4 > UAS-PLCG1Reference or UAS-PLCG1H380R flies are
viable at the three tested temperatures (29°C, 25°C, and 22°C). In contrast, *da-GAL4 > UAS-PLCG1<sup>D1019G</sup>* or *UAS-PLCG1<sup>D1165G</sup>* flies are lethal at 29°C, semi-lethal (~80%-85% lethal) at 25°C, and viable at 22°C (Figure 4C, right panel). The animals that escape lethality at 25°C have smaller pupae (Figure S2) and a reduced adult body size, showing that growth is impeded. In summary, these data consistently confirmed that ubiquitous elevated expression levels of the human *PLCG1* is toxic in flies.

To assess other phenotypes, we used *nub-GAL4* to mostly drive the expression of *UAS-PLCG1* or *UAS-sl* cDNAs in the wing disc, a well-established model to study growth and differentiation in a tissue that is dispensable for viability. Overexpression of either *PLCG1<sup>Reference</sup>* or *sl<sup>WT</sup>* in the wing disc leads to slightly smaller wings with a ~10% reduction in size when compared to expressing the *UAS-Empty* control (Figure S3). Hence, both loss and overexpression of *sl* in the wing lead to a size reduction (Figure 2B and S3). This implies a potential dosage-dependent regulation on wing growth by the PLCγ isozymes, although the underlying mechanism is unknown. Overexpression of the *PLCG1<sup>H380R</sup>* or *sl<sup>H384R</sup>* in the wing results in ~5% reduction in wing size when compared to the *PLCG1<sup>Reference</sup>* or *sl<sup>WT</sup>* (Figure S3). However, overexpression of *PLCG1<sup>D1019G</sup>* or *PLCG1<sup>D1165G</sup>* results in severe wing phenotypes characterized by notched wing margins, fused/thickened veins and reduced wing sizes (Figure 5A). Notably, overexpressing fly *sl<sup>D1041G</sup>* leads to very similar morphological defects as the corresponding human *PLCG1<sup>D1019G</sup>* variant, indicating that the observed wing phenotypes are indeed due to alterations in *PLCG1/sl* functions. These data also argue that the human *PLCG1* functions in the same pathways as *sl*. Furthermore, overexpressing the *sl<sup>D1184G</sup>* leads to pupal lethality (Figure 5A). This suggests that this variant has a more severe impact on development than the other variants and is not inconsistent with the observation that *nub-GAL4* drives some expression of *UAS-cDNA* in the nervous system as well.

We also assessed the effect of ectopic expression of human *PLCG1* on eye development using an eye-specific driver *eyeless-GAL4* (*ey-GAL4*). The expression of *PLCG1<sup>Reference</sup>* or *PLCG1<sup>H380R</sup>* in fly eyes leads to a mild reduction in eye size, while the expression of *PLCG1<sup>D1019G</sup>* or *PLCG1<sup>D1165G</sup>* leads to a severe reduction in eye size (Figure S4). In summary, the eye data are consistent with the wing data, showing
that $PLCG1^{D1019G}$ and $PLCG1^{D1165G}$ are more toxic than $PLCG1^{Reference}$. On the other hand, the toxicity of $PLCG1^{H380R}$ is milder and can be distinguished from that of the $PLCG1^{Reference}$ only in certain contexts.

The p.Asp1019Gly and p.Asp1165Gly variants are gain-of-function variants

Previous studies have identified a very strong gain-of-function somatic $PLCG1$ variant p.Asp1165His in adult T cell leukemia/lymphoma\textsuperscript{20,70,71}. This variant has been documented to cause a very dramatic increase in phospholipase activity \textit{in vitro}\textsuperscript{20,71}. To characterize the impact of this hyperactive variant \textit{in vivo}, we generated transgenic flies with this variant and tested $PLCG1^{D1165H}$ in our tissue-specific expression assays. Overexpression of $PLCG1^{D1165H}$ in the eye using \textit{ey-GAL4} causes lethality at 29°C (Figure S4), arguing that it is highly toxic. As shown in Figure 5B, overexpressing $PLCG1^{D1165H}$ in the wing using the \textit{nub-GAL4} driver causes lethality at 29°C. However, these flies survive when they are raised at 25°C, yet the wings show severe morphological defects, including notched wing margins, thickened veins as well as reduced wing size. These phenotypes are similar to, but more severe than, the defects observed in the wings overexpressing $PLCG1^{D1019G}$ or $PLCG1^{D1165G}$ (Figure 5B). These data provide compelling evidence that these two variants are gain-of-function variants.

Discussion

A recent study reported an individual with a \textit{de novo} heterozygous gain-of-function germline variant in $PLCG1$, p.Ser1021Phe\textsuperscript{72}. The proband exhibited an early-onset and severe immune dysregulation with autoimmune and autoinflammatory symptoms. Tao \textit{et al.} performed \textit{in vitro} and \textit{ex vivo} experiments using cultured cell lines transfected with $PLCG1$ constructs and peripheral blood mononuclear cells from the proband, respectively. They showed that the p.Ser1021Phe variant led to a 1.5-2 fold increase in intracellular IP3 production compared to controls. However, in our \textit{in vivo} assays, overexpression of $PLCG1^{S1021F}$ in wings or eyes does not cause obvious phenotypes when compared to $PLCG1^{Reference}$.
which is clearly distinct from the other gain-of-function variants tested in our assays (p.Asp1019Gly, p.Asp1165Gly and p.Asp1165His) (Figure 5B). It is notable that the three probands reported here are discordant for immune-related phenotypes. Proband 1 with the p.Asp1019Gly variant has no immune dysregulation symptoms. Proband 2 with the p.His380Arg variant has a relapsing steroid responsive inflammatory encephalomyelitis, which is very different from the autoimmune symptoms reported by Tao et al.\textsuperscript{72} Finally, proband 3 with the p.Asp1165Gly variant presents with a T cell lymphocytopenia with recurrent infections suggesting that the individual is immune compromised. Hence, the immune phenotypes in the individuals reported here are very heterogeneous or absent, and inconsistent with an autoimmune disease. In summary, the immune-related phenotypes and their association with \textit{PLCG1} variants will need to be explored in more depth.

Previously, studies based on biochemical assays and protein structures provided insights into how the variants studied here may affect the enzymatic activity of PLC\textgreek{g}1 (the established protein structure of full-length rat Plcg1 is shown in Figure 6A). In its basal state, the PLC\textgreek{g}-specific regulatory array (sPH-nSH2-cSH2-SH3) forms autoinhibitory interfaces with the catalytic domains. Upon activation by the RTKs through binding to nSH2, PLC\textgreek{g}1 is phosphorylated, which in turn induces the dissociation of the inhibitory cSH2 domain from the C2 domain. This triggers conformational rearrangements, allowing the enzyme to associate with the membrane and exposing the catalytic domains to allow hydrolysis of PIP\textsubscript{2}\textsuperscript{19-21,73,74}. As shown in Figure 6A, the location of the three variants modeled in this study (Asp1019Gly, His380Arg and Asp1165Gly) are either within the catalytic domains or at the intramolecular interfaces. The p.Asp1019Gly and p.Asp1165Gly variants impact crucial residues involved in autoinhibition. Specifically, the p.Asp1019Gly variant affects a residue located at the apex of the hydrophobic ridge within the Y box (Figure 6B), which is important for the interaction between the sPH domain and the Y box. This interaction is critical for the autoinhibition by blocking the membrane engagement of the catalytic core domain prior to enzymatic activation\textsuperscript{20,75}. Notably, substitution of Asp1019 with Lys (D1019K) has been demonstrated to enhance basal phospholipase activity by approximately 15 fold.\textsuperscript{in}
Similarly, another hotspot somatic variant, p.Ser345Phe, located at the hydrophobic ridge within the X box, involved in the interaction between the sPH domain and X box, has also been verified to be hyperactive. In contrast, the p.Ser1021Phe variant described by Tao et al. lies outside the hydrophobic ridge of the interface between the sPH domain and Y box (Figure 6B). On the other hand, the p.Asp1165Gly variant affects a residue situated within a loop of the C2 domain (Figure 6C). The Asp1165 residue plays a key role in stabilizing the interaction between the cSH2 domain and the C2 domain to maintain the autoinhibited state. As mentioned above, the somatic variant p.Asp1165His leads to significantly elevated phospholipase activity in vitro, and results in severe phenotypes in vivo (Figure 5B). In contrast, the p.His380Arg variant impacts the His380 residue within the X box, situated near the bound Ca\(^{2+}\) cofactor in the catalytic core (Figure 6D). His380 plays a role in coordination of phosphate 1 of IP3. While this residue may not be key to the autoinhibition, it is important to the phospholipase activity. Substitution of His380 with Phe or Ala (H380F, H380A) has been reported to suppress PIP2 hydrolysis and IP3 production. Substitution of the His380 with Arg in p.His380Arg variant may create a more basic environment, impacting the lipase activity in a distinct way. Our in vivo data are consistent with the published in vitro data, strengthening our conclusion that the variants are pathogenic and impact the protein function.

In summary, we report three individuals with de novo heterozygous missense variants in PLCG1 presenting with disease features that encompass ophthalmologic, hearing, and cardiac defects with variable expressivity. Our functional assays provide compelling in vivo evidence that the PLCG1 variants alter normal protein function. However, additional genetic variants (see Table 1) and environmental factors may contribute to some of the diverse phenotypes observed in these three individuals. Moreover, the PLC\(\gamma\)1 isoform is an integral component of multiple signaling pathways, and the outcomes of its dysregulation are expected to be context dependent. Hence, different variants of PLCG1 may impact diverse cellular processes in different tissues and cells, leading to a range of pathological changes. Even when the affected residues are in close proximity to each other, their impact on protein function can be
different\textsuperscript{73}. Moreover, given that the p.Asp1019Gly and p.Asp1165Gly variants are hyperactive, potential therapeutic targets include specific inhibitors of PLCG1, such as antisense approaches that target the altered nucleotides\textsuperscript{81,82}.

**Data and code availability**

This study did not generate datasets. All reagents developed in this study are available upon request.

**Conflict of Interest Statement**

The Department of Molecular and Human Genetics at Baylor College of Medicine receives revenue from clinical genetic testing completed at Baylor Genetics Laboratories.

**Acknowledgments**

We thank the probands and families for their participation in this study. We thank Ms. Hongling Pan for transgenic fly lines. We thank Dr. Meisheng Ma for suggestions about protein structure interpretation. We thank the Bloomington Drosophila Stock Center (BDSC) for providing stocks.

**Funding Statement**

This work was supported by the Huffington Foundation; the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital, and the Undiagnosed Diseases Network funded by grants from the National Institutes of Health (U01 HG010233, U01 NS134355, U01 HG007709, U01 HG007942). Sequence data analysis was supported by the University of Washington Center for Rare Disease Research (UW-CRDR; U01 HG011744, UM1 HG006493, U24 HG011746). The content is solely the responsibility
of the authors and does not necessarily represent the official views of the National Institutes of Health. H.J.B. receives support from the NIH Common Fund through the Office of Strategic Coordination/Office of the NIH Director and the NINDS (U54 NS093793) as well as ORIP (R24 OD022005 and R24 OD031447). Confocal microscopy was performed in the BCM IDDRC Neurovisualization Core, supported by the NICHD (U54 HD083092).

Author contributions

Figures and Figure Legends

Figure 1. The PLCG1 homolog, sl is conserved in Drosophila

(A) Schematic of human PLCG1 and fly Sl protein domains and positions of the variants identified in the probands. Domain prediction is based on annotation from NCBI. Alignment of human PLCG1 and the homologous proteins. The variants are marked with boxes.

(B) All the variants affect conserved amino acids (labeled in red). Isoforms for alignment: Human PLCG1 NP_877963.1; Mouse Plcg1 NP_067255.2; Zebrafish plcg1 NP_919388.1; Fly sl NP_476726.2.

(C) Schematic of fly sl genomic span, transcript, alleles and the 92kb genomic rescue (GR) construct. Loss-of-function alleles of sl including slD (13bp deletion 52), slKO (CRISPR-mediated deletion of the gene span 53), and slT2A (T2A cassette inserted in the first intron, 54) are indicated. The T2A cassette in slT2A is flanked by FRT sites and can be excised by Flippase to revert loss-of-function phenotypes. GAL4 expression in slT2A under the control by sl endogenous promoter can be used to assess sl gene expression pattern by crossing with a UAS-mCherry.nls reporter line, or be used to model patient variants in vivo by crossing with human PLCG1 cDNAs or corresponding fly sl cDNAs. The primer pair used for real-time PCR is indicated.

Figure 2. slT2A is a loss-of-function allele causing phenotypes in wing and eye

(A) sl expression in wing and eye. Expression of UAS-mcherry.nls (red) was driven by slT2A to label the nuclei of the cells that expressed sl. sl is expressed in the 3rd instar larval wing disc (left) and eye disc (right). Higher magnification image of the wing disc pouch region indicated by dashed rectangle is shown. The posterior/anterior and dorsal/ventral compartment boundaries are indicated by dashed lines in yellow. Scale bars, 100μm

(B) slT2A causes wing size reduction and ectopic veins (arrowhead) in hemizygous mutant male flies. The wing phenotypes can be rescued by introduction of a genomic rescue (GR) construct or the
expression of Flippase. Scale bars, 0.5mm. The quantification of adult wing size is shown in the right panel. Each dot represents the measurement of one adult wing sample. Unpaired t test, ****p < 0.0001, mean ± SEM.

(C) slT2A causes extra photoreceptors (arrows) in the hemizygous mutant flies. The eye phenotype can be rescued by introduction of a genomic rescue (GR) construct. The photoreceptor rhabdomeres stain positive for phalloidin labeling F-actin. Scale bars, 10μm. The quantification is shown in the right panel. Each dot represents the measurement of one retina sample. Unpaired t test, ****p < 0.0001, mean ± SEM.

Figure 3. sl is expressed in a subset of neurons and glia in the CNS, and loss of sl causes behavioral defects

(A) Expression pattern of sl in the central nervous system observed by slT2A-driven expression of UAS-mCherry.nls reporter (red). In either larval or adult brain, sl is expressed in a subset of fly neurons and glia, which were labeled by pan-neuronal marker Elav (green, upper panel) and pan-glia marker Repo (green, lower panel). Higher magnification images of the regions indicated by dashed rectangles are shown. Scale bars, 20μm in the magnified images, 50μm in other images.

(B) Loss of sl causes behavioral defects in longevity and locomotion. slT2A hemizygous flies have a shorter lifespan than w1118 control flies. The median life span of slT2A and w1118 flies is 40 days and 62 days respectively. The short lifespan in slT2A flies can be rescued by a UAS transgene that expresses wild-type sl cDNA (slWT). Fly locomotion ability was assessed by climbing assay (see methods). slT2A flies at the age of 7 days show reduced locomotion ability and become almost immotile at the age of 35 days. The reduced locomotion ability in slT2A flies can be fully rescued by slWT. For lifespan assay, Longrank test, ****p<0.0001. For climbing assay, each dots represents one vial containing 18-22 flies for test. Unpaired t test, ****p<0.0001.

Figure 4. The variant cDNAs are toxic
(A) Summary of the viability of expressing sl or PLCG1 cDNAs in slT2A mutant flies. Cross strategy: heterozygous slT2A female flies were crossed to male flies carrying UAS-cDNAs or control (UAS-Empty) constructs, or crossed to the y w males as an extra control. The percentages of the hemizygous slT2A male progeny expressing different UAS-cDNA constructs were calculated. The expected Mendelian ratio is 0.25 (indicated by the green line in the graph). The dark gray columns represent human cDNAs, the light gray columns represent fly cDNAs, and the clear columns represent controls (y w or UAS-Empty). Each dot represents one independent replicate. Unpaired t test, *p<0.05, ****p < 0.0001, mean ± SEM.

(B) Summary of the viability of ubiquitous overexpression of sl or PLCG1 cDNAs driven by Tub-GAL4. Expression of wild-type fly sl cDNA shows no impact on viability whereas expression of the sl variants reduces viability. Expressing human PLCG1 cDNAs at 29°C is toxic in flies. Expression of PLCG1Reference or PLCG1H380R causes semi-lethality, whereas expression of PLCG1D1019G or PLCG1D1165G is 100% lethal at early larval stage.

(C) Summary of the viability of ubiquitous overexpression PLCG1 cDNAs using a strong driver Tub-GAL4 (left panel) or a weaker driver da-GAL4 (right panel) at different temperatures. The expression level rises with higher temperatures and decreases with lower temperatures, and the toxic impact on viability correlates with the expression level. Expression of PLCG1D1019G or PLCG1D1165G causes more severe toxicity than expression of PLCG1Reference or PLCG1H380R.

Figure 5. The PLCG1 p.Asp1019Gly and p.Asp1165Gly variants are likely to be gain-of-function alleles

(A) Wing-specific overexpression of PLCG1D1019G or PLCG1D1165G causes severe wing morphology defects including notched margin (arrows) and fused/thickened veins (arrowheads), fully penetrant (the penetration ratio is indicated). Note that overexpression of the fly slD1041G (corresponding to the human PLCG1D1019G) shows similar phenotypes. Scale bars, 0.5mm.
(B) Wing-specific overexpression of an established hyperactive variant $\text{PLCG1}^{D1165H}$ causes wing morphology phenotypes similar to, but more severe than that of $\text{PLCG1}^{D1019G}$ or $\text{PLCG1}^{D1165G}$.

Scale bars, 0.5mm.

Figure 6. $\text{PLCG1}$ variants affect important residues

(A) 3D structure of full-length rat Plcg1 (PDB code: 6PBC; rat Plcg1 shares 96.9% amino acid identity with human PLCG1). The conserved protein domains are labeled with different colors. Two major intracellular interfaces are circled by dashed lines: 1-The hydrophobic ridge between the sPH domain and the catalytic core (X-box and Y-box); and 2-The interface between the cSH2 domain and the C2 domain. The three residues affected by the variants are indicated by yellow balls.

(B) Enlarged views of the Asp1019 residue within the autoinhibition interface between sPH domain and the Y box. The potential interactions with nearby residues are indicated. Notably, the Ser1021 residue is outside of the hydrophobic ridge and shows no predicted interaction with the residues in the sPH domain.

(C) Enlarged views of the Asp1165 residue within the autoinhibition interface between the cSH2 domain and the C2 domain. The potential interactions with nearby residues are indicated.

(D) Enlarged view of the His380 residue within the X-box catalytic domain, in proximity to the $\text{Ca}^{2+}$ cofactor. Structural analysis was performed via UCSF Chimera\textsuperscript{83}.
The Undiagnosed Diseases Network Consortia

References


24


A The proband variants are in the conserved protein domains

**Human PLCG1** (NP_877963.1)

- p.H380R
- p.H380R
- p.H380R

**Fly Sl** (NP_476726.2)

- p.H384R
- p.H384R
- p.H384R

B The proband variants affect conserved amino acids cross species

- **Human_PLCG1**
  - p.H380R: **V I Y H G H T L T**
  - p.H380R: **V I Y H G H T L T**
  - p.H380R: **V I Y H G H T L T**
- **Mouse_Plcg1**
  - p.D1019G: **Q R L D S S N Y D**
  - p.D1019G: **Q R L D S S N Y D**
  - p.D1019G: **Q R L D S S N Y D**
- **Zebrafish_plcg1**
  - p.D1041G: **Q R L D S S F N N**
  - p.D1041G: **Q R L D S S F N N**
  - p.D1041G: **Q R L D S S N Y D**
- **Fly_Sl**
  - p.D1165G: **V Y E D M F S D Q**
  - p.D1165G: **V Y E D M F S D Q**
  - p.D1165G: **V Y E D M F S D Q**

C sl reagents

- **Genomic Rescue (GR): Dp(1;3)DC313**
- **s/* gene**
  - **X chromosome**: sl
  - **1kb**
- **s/* transcripts and alleles**
  - sl
  - sl
  - sl
  - sl
- **mRNA**
  - T2A
  - GAL4
  - polyA
  - 3XP3GFP
- **Protein**
  - T2A
  - GAL4
  - polyA
  - Truncated Sl
- **Cassette excision with FRT-FLP**
- **Revert phenotype**
- **Gene expression pattern**
- **Model the variants in vivo**
A  sl is expressed in the developing wing and eye discs

\[ \text{sll}^{T2A} \text{ > UAS-mCherry.nls} \]

25°C

Wing disc

Eye disc

B  sl^{T2A} causes ectopic veins and reduction in the size of the adult wings

\[ W^{1118} / Y \quad \text{sl}^{T2A} / Y \quad \text{sl}^{T2A} / Y; \text{GR} / + \quad \text{sl}^{T2A} / Y; \text{UAS-Flp} / + \]

\[
\begin{array}{c}
\text{Adult wing size (mm²)} \\
\text{0.0} \quad \text{0.5} \quad \text{1.0} \quad \text{1.5}
\end{array}
\]

C  sl^{T2A} causes extra R7 photoreceptors in the adult eyes

\[ W^{1118} / Y \quad \text{sl}^{T2A} / Y \quad \text{sl}^{T2A} / Y; \text{GR} / + \]

\[
\begin{array}{c}
\% \text{Ommatidia with abnormal photoreceptor number} \\
0 \quad 20 \quad 40 \quad 60 \quad 80
\end{array}
\]
**A** *sl* is expressed in a subset of neurons and glia in the CNS

\[ sl^{T2A} > UAS-mCherry.nls \]

<table>
<thead>
<tr>
<th>Neurons</th>
<th>Adult brain</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elav mCherry</td>
<td>Elav mCherry</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Glia</th>
<th>Adult brain</th>
</tr>
</thead>
<tbody>
<tr>
<td>Repo mCherry</td>
<td>Repo mCherry</td>
</tr>
</tbody>
</table>

---

**B** Loss of *sl* causes behavioral defects including reduced lifespan and locomotor defect

**Lifespan**

\[ W^{1118} / Y \quad sl^{T2A} / Y \quad sl^{T2A} / Y > sl^{WT} \]

**Climbing**

\[ W^{1118} / Y \quad sl^{T2A} / Y \quad sl^{T2A} / Y > sl^{WT} \]
A Expression of UAS-sl or UAS-PLCG1 cDNAs in slT2A mutant flies

Cross Strategy

\[
\begin{array}{c}
sl^{T2A} / Balancer \\
yw / Y; UAS-cDNA (or +) \\
\downarrow \\
Progeny \\
\end{array}
\]

sl^{T2A} / yw 
sl^{T2A} / Y 
Balancer / Y 
Balancer / yw

Expected Mendelian Ratio for each genotype is 0.25

B Ubiquitous overexpression of UAS-sl or UAS-PLCG1 using Tub-GAL4

\[
\begin{array}{cccc}
& \text{Tub-GAL4 > UAS-sl cDNA} & 29^\circ \text{C} \\
\text{Wild-type} & \text{H384R} & \text{D1041G} & \text{D1184G} \\
\text{Viable} & \text{Semi-lethal} & \text{L1-L2 lethal} & \text{L1-L2 lethal} \\
\text{Reference} & \text{H380R} & \text{D1019G} & \text{D1165G} \\
\text{Semi-lethal} & \text{Semi-lethal} & \text{L1-L2 lethal} & \text{L1-L2 lethal} \\
\end{array}
\]

C The toxicity caused by overexpressing human PLCG1 cDNA is dosage sensitive
Figure 5. The PLCG1p.Asp1019Gly and p.Asp1165Gly variants are likely to be gain-of-function alleles

A Wing-specific overexpression of PLCG1D1019G, PLCG1D1165G or their corresponding fly variants severely affect wing morphology

<table>
<thead>
<tr>
<th></th>
<th>Reference</th>
<th>D1019G</th>
<th>D1165G</th>
</tr>
</thead>
<tbody>
<tr>
<td>PLC1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wild-type</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sl</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Empty</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B Comparison between the established somatic hyperactive PLCG1D1165H and the genetic PLCG1D1019G, PLCG1D1165G variants

<table>
<thead>
<tr>
<th></th>
<th>D1019G</th>
<th>D1165G</th>
<th>D1165H</th>
</tr>
</thead>
<tbody>
<tr>
<td>Expression level</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>29°C</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25°C</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Wing-specific overexpression of PLCG1D1019G, PLCG1D1165G or their corresponding fly variants severely affect wing morphology.

Comparison between the established somatic hyperactive PLCG1D1165H and the genetic PLCG1D1019G, PLCG1D1165G variants.
Figure 6. *PLCG1* variants affect important residues
**Supplemental Data**

**Additional variants identified in the probands**

Proband 1 carries an intragenic duplication in **PSD3**. **PSD3** has not been associated with a Mendelian disorder but is potentially associated with an autosomal dominant arthrogryposis \(^1\). Hence, it may underlie the joint defects observed in proband 1.

Proband 2 has compound heterozygous missense variants in **ERAP2** and **SEMA3G**. **ERAP2** [MIM: 609497] has not been associated with a Mendelian disorder. It encodes an ER-residential metalloaminopeptidase that functions in the major histocompatibility class I antigen presentation pathway. Some variants in **ERAP2** are associated with a susceptibility to autoimmune diseases such as ankylosing spondylitis and Crohn’s disease \(^2\)-\(^4\). Given that proband 2 exhibits neuroinflammation and encephalitis, these phenotypes may be associated with the **ERAP2** variants. **SEMA3G** (Semaphorin 3G) has not been associated with a Mendelian disorder. However, a homozygous missense variant in **SEMAG3** was observed in two affected siblings from a consanguineous family. The siblings exhibited dysmorphic features as well as developmental delay \(^5\).

Proband 3 carries a *de novo* missense variant in **PKP2** [MIM: 602861]. **PKP2** encodes Pakophilin-2 and has been associated with dominant arrhythmogenic right ventricular dysplasia \(^6\)-\(^8\) [MIM: 609040]. However, this proband was born with septal defects.

**Expression of human **PLCG1** reduces the viability of sl\(^{T24}\) hemizygotes, and **PLCG1\(^\text{Reference}\)** shows no obvious rescue of the phenotypes in the wings and eyes caused by loss of **sl****

We assessed if human **PLCG1** could effectively serve as a functional substitute for fly **sl** and rescue the loss-of-function phenotypes observed in **sl** mutant flies. However, only a small fraction of the **sl\(^{T24}/Y\)** mutant hemizygotes expressing **PLCG1\(^\text{Reference}\)** can survive to adults (Figure 4A). In addition to the obvious toxicity, **PLCG1\(^\text{Reference}\)** fails to rescue the phenotypes observed in the wings or eyes of the **sl** mutant flies (Figure S6), which is fully rescued by fly **sl\(^{WT}\)** (Figure 2). This suggests that despite their high DIOPT score, human **PLCG1** cannot fully substitute for fly **sl**. It is possible that during the course of
evolution, *PLCG1* has acquired more specialized functions. For example, an essential step for enzymatic activation of mammalian PLCγ is the binding of its nSH2 domain to specific phosphotyrosines on the RTKs through a specific binding motif. However, Thackeray *et al.* found that the consensus motif is absent in the intracellular domain of the *Drosophila* EGF receptor homolog DER, one of the three RTKs in *Drosophila* which is required for wing vein differentiation and photoreceptor formation.
Supplemental Figures and Legends

Figure S1. *slT2A* is a loss-of-function allele causing wing and eye phenotypes

(A) Relative *sl* mRNA expression are <5% and <1% in *slT2A* and *slKO* mutant larvae when compared to controls (*w^{1118})*. The primers used for real-time PCR are shown in Figure 2A. Each dot represents a replicate per genotype. Unpaired t test, ***p<0.001.

(B) Representative images showing that *slT2A*/*sl2* trans-heterozygous mutant flies have smaller wing and ectopic veins (indicated by arrow). Scale bars, 0.5mm.

(C) Representative images showing that *slT2A*/*slKO* trans-heterozygous mutant flies have extra photoreceptors (indicated by arrows). The schematic of the section of an ommatidia presenting seven photoreceptors (the R8 photoreceptor is not visible in such section) is shown. The photoreceptor rhabdomeres stain positive for phalloidin labeling F-actin. Scale bar, 10μm.
**Figure S2. Ubiquitous overexpressing of** $PLCG1^{D1019G}$ **or** $PLCG1^{D1165G}$ **driven by da-GAL4 causes pupal size reduction**

<table>
<thead>
<tr>
<th>da-GAL4 &gt; UAS-PLCG1 cDNA</th>
<th>25°C</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reference</td>
<td>D1019G</td>
</tr>
</tbody>
</table>

Representative images showing the pupal size of animals overexpressing $PLCG1$ cDNAs by da-GAL4 at 25°C. Overexpression of $PLCG1^{D1019G}$ or $PLCG1^{D1165G}$ causes pupae size reductions when compared to $PLCG1^{Reference}$. Overexpression of $PLCG1^{H380R}$ is indistinguishable from $PLCG1^{Reference}$. Scale bars, 0.5mm.
Figure S3. Wing-specific overexpression of $PLCG1^{\text{Reference}}$ or $sl^{\text{WT}}$ causes wing size reduction, while overexpressing the $PLCG1^{H380R}$ or $sl^{H384R}$ further reduces wing size.

Representative images showing that wing-specific overexpression of $PLCG1^{\text{Reference}}$ or $sl^{\text{WT}}$ causes ~15% wing size reduction compared to the UAS-Empty control construct. Overexpression of $PLCG1^{H380R}$ or $sl^{H384R}$ causes a further ~5% size reduction. Each dot represents one measured adult wing. Unpaired t test, ***p<0.001, ****p < 0.0001, mean ± SEM. Scale bars, 0.5mm.
Figure S4. Eye-specific overexpression of human PLCG1 leads to size reduction in the eyes, and expression of the PLCG1\textsubscript{D1019G} or PLCG1\textsubscript{D1165G} causes more severe phenotype than expression of PLCG1\textsubscript{Reference} or PLCG1\textsubscript{H380R}.

Representative images showing that eye-specific overexpression of PLCG1\textsubscript{Reference} or PLCG1\textsubscript{H380R} causes \sim15\% eye size reduction compared to the UAS-Empty control construct, whereas overexpression of PLCG1\textsubscript{D1019G} or PLCG1\textsubscript{D1165G} causes a \sim30\% size reduction. Overexpression of PLCG1\textsubscript{D1165H} causes lethality. Each dot represents one measured adult eye. Unpaired t test, **p<0.01, ****p < 0.0001, ns: not significant, mean ± SEM. Scale bars, 100\mu m.
Figure S5. Ectopic expression of $PLCG1^{S1021F}$ causes indistinguishable phenotypes in the wings or eyes compared to $PLCG1^{Reference}$.

Representative images showing the adult wings and eyes with $PLCG1^{S1021F}$ overexpression using $nub$-$GAL4$ or $ey$-$GAL4$, respectively. There is no obvious morphological difference compared to $PLCG1^{Reference}$. Scale bars, 0.5mm in the wing images, 100µm in the eye images.
Figure S6. Expressing human *PLCG1* does not rescue wing and eye phenotypes associated with *sl^{T2A}*

Representative images showing the adult wings (upper panel) and the photoreceptors (lower panel) expressing *PLCG1\textsuperscript{Reference}* or *sl\textsuperscript{WT}*.

Expression of *sl\textsuperscript{WT}* rescues the loss-of-function phenotypes including wing size reduction, ectopic veins (indicated by red arrows) and extra photoreceptors (indicated by yellow arrows), whereas expression of the *PLCG1\textsuperscript{Reference}* or *UAS-Empty* shows no rescue. Scale bars, 0.5mm for the wing images and 10μm for the photoreceptor images. The photoreceptor rhabdomeres stain positive for phalloidin labeling F-actin. Quantification of the wing size (upper right panel) and the photoreceptors (lower right panel) are shown. Each dot represents one wing or one retina sample, respectively. Unpaired t test, ***p<0.001, *p<0.05. ns: not significant.
Supplemental Tables

Table S1. Pathogenicity prediction of the proband variants
Table S2. Mammalian PLC coding genes and their fly orthologs
Table S3. Fly strains used in the experiments
Table S4. Primers used in the experiments

Material and methods

Recruitment of the probands

Formal consents for genetic testing and publication were obtained from all probands or their family members. Probands 1 and 2 were recruited through the Undiagnosed Diseases Network (UDN) and were evaluated through the clinical research protocol of the National Institutes of Health Undiagnosed Diseases (15-HG-0130), which was approved by the National Human Genome Research Institute (NHGRI). Proband 3 was recruited through GeneMatcher.

Drosophila husbandry and generation of transgenic flies

The fly strains used in this study (listed in Table S3) were generated in house or obtained from the Bloomington Drosophila Stock Center (BDSC). All the flies were raised and maintained on standard fly food at room temperature unless specified. The sl$^{T2A}$ allele was outcrossed with w$^{118}$ to clean up the genetic background. The strains used in this study were listed in Supplemental Table S3.

To generate the UAS-cDNA transgenic lines, human $PLCG1$ cDNA was obtained from Horizon Discovery (MHS6278-213246131, clone ID 9052656), and fly sl cDNA was obtained from Drosophila Genomics Resource Center (DGRC, RE62235). The coding sequence (CDS) of $PLCG1^{Reference}$ and sl$^{WT}$ were amplified using iProof™ High-Fidelity DNA Polymerase Kit (BioRad, #1725301), purified using QIAEX II Gel Extraction Kit (QIAGEN, #20021), sub-cloned into the Gateway compatible entry vector pDONR223 by BP cloning (BP clonase II, Thermo Fisher Scientific, #11789020) and sequentially cloned
into the destination vector pGW-attB-HA by LR cloning (LR clonase II, Thermo Fisher Scientific, #11791100)\textsuperscript{14}. The variants were generated by site-directed mutagenesis strategy using Q5 Hot Start High-Fidelity 2x Master Mix (NEB, #M0494S) and \textit{DpnI} restriction enzyme (NEB, # R0176L). All the constructs were sanger verified and injected, and inserted into the VK33 (\textit{PBac[y[+]-attP]}VK00033) docking site using \textit{\phi}C31 mediated transgenesis \textsuperscript{15,16}. Primers are listed in Supplemental Table S4.

\textbf{\textit{Drosophila} behavioral assays}

The climbing assay to examine the negative geotaxis and locomotion ability of the flies was performed as previously described \textsuperscript{17,18} with some modifications. 18-22 flies per vial were transferred to an empty plastic vial and given 20min to rest prior to being tested. The flies were tapped to the bottom of the vial and were allowed to climb for 15s. The percentage of flies per vial that climbed over 5cm were calculated. The maximum distance from the bottom to the top is 18.5cm.

For the lifespan assay, newly eclosed male flies were collected and maintained at 25 °C (10 flies per vial). The flies were transferred to a new vial and the number of dead flies was counted every two days.

\textbf{Immunostaining}

Fly tissues were dissected in 1x PBS, fixed in 4% paraformaldehyde for 20min at room temperature, and washed in PBS (3 x 10min). For antibody staining, samples were treated with PBST (Triton X-100 in PBS, 0.1% for larval tissues, 2% for adult brain), 5% normal goat serum, and incubated in primary antibody overnight at 4°C. Samples were washed with 0.1% PBST (3 x 10min) and incubated with secondary antibody for 2h at room temperature (in darkness) and washed in 0.1% PBST (3 x 10min). Primary antibodies: rat anti-\textit{Drosophila} Elav (1:250, DSHB, #7E8A10); mouse anti-\textit{Drosophila} Repo (1:50, DSHB, #8D12). Secondary antibodies: goat anti-rat-647 (1:250, Jackson ImmunoResearch, #112-605-003), goat anti-mouse-Cy5 (1:250, Invitrogen, #A10524). Larval discs were mounted in Vectashield (Vector Labs #H1200 and #H1000). Larval CNS and adult brain were mounted in Rapiclear (Cedarlane,
For adult retinas, flies are reared at 25 °C under 12-h light/dark conditions. Retinas were isolated from 5-7 day old flies. Heads were dissected in PBS and fixed in 3.7% formaldehyde overnight at 4°C. The samples were rinsed with 0.1% PBST and the retinas were subsequently dissected and incubated with PBST-diluted phalloidin 647 (1:100, Invitrogen, #A22287) for 1h. Retinas were washed in 0.1% PBST and mounted in Vectashield. The images were obtained with a confocal microscope (Leica SP8X or Zeiss Airyscan LSM 880) and processed using the ImageJ-FIJI software.

Imaging of adult fly wings and eyes

To prepare the samples of adult fly wings, the wing blades were dissected and mounted in a glycerol/ethanol 1/1 mixture. Only wings from the same gender were compared to each other since females have larger wings than males when raised in the same conditions. To prepare the samples of adult fly eyes, the flies were frozen and placed onto a double-side stick tape with one eye facing up. The samples were imaged using bright field Stereomicroscope (Leica MZ16 or Leica Z16 APO). Image Pro Plus 7.0 software was used to for extended depth-of-field images. The image processing and the measurement of the total areas of the wing blades or eyes were conducted using the ImageJ-FIJI software.

Real-time PCR

Real-time PCR was performed as previously described with modifications. All-In-One 5X RT MasterMix (abm, #G592), iTaq Universal SYBR Green Master Mix (BioRad#1725120) and BioRad C1000 Touch Cycler were used. Primers are listed in Supplemental Table S4.
Supplemental References